Oxford BioMedica plc (LON:OXB) Given New GBX 8.70 Price Target at N+1 Singer
Oxford BioMedica plc (LON:OXB) had its target price increased by equities researchers at N+1 Singer from GBX 7.80 ($0.10) to GBX 8.70 ($0.11) in a report released on Thursday. The firm currently has a “hold” rating on the biopharmaceutical company’s stock. N+1 Singer’s price target points to a potential upside of 1.16% from the stock’s previous close.
A number of other brokerages also recently commented on OXB. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 13 ($0.17) target price on shares of Oxford BioMedica plc in a report on Thursday, July 13th. Shore Capital restated a “not rated” rating on shares of Oxford BioMedica plc in a report on Thursday, July 13th.
Shares of Oxford BioMedica plc (OXB) traded down 1.05% during midday trading on Thursday, hitting GBX 8.51. 449,513 shares of the stock were exchanged. Oxford BioMedica plc has a 1-year low of GBX 2.98 and a 1-year high of GBX 11.25. The firm has a 50-day moving average of GBX 7.40 and a 200-day moving average of GBX 5.30. The company’s market capitalization is GBX 262.45 million.
In other news, insider Lorenzo Tallarigo bought 49,033 shares of the company’s stock in a transaction that occurred on Friday, June 23rd. The shares were purchased at an average price of GBX 5 ($0.07) per share, for a total transaction of £2,451.65 ($3,193.92). Also, insider Martin Diggle bought 660,000 shares of the company’s stock in a transaction that occurred on Thursday, July 13th. The stock was purchased at an average price of GBX 9 ($0.12) per share, for a total transaction of £59,400 ($77,384.05). In the last 90 days, insiders have bought 1,011,980 shares of company stock worth $8,448,961.
Oxford BioMedica plc Company Profile
Oxford BioMedica plc is a gene and cell therapy company. The Company is engaged in lentiviral vector and cell therapy research, development and production. The Company’s segments include Partnering, and R&D. The Partnering segment provides lentiviral vector bioprocessing and process development services to partners.
Receive News & Ratings for Oxford BioMedica plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica plc and related companies with MarketBeat.com's FREE daily email newsletter.